Search results

    Search results

    Show all results for ""
    Can not find any results or suggestions for "."

    Search tips

    • Make sure there are no spelling errors
    • Try different search terms or synonyms
    • Narrow your search for more hits

    How can we help?

    Contact Us

    Find Employees

    University of Skövde, link to startpage

    Search results

      Search results

      Show all results for ""
      Can not find any results or suggestions for "."

      Search tips

      • Make sure there are no spelling errors
      • Try different search terms or synonyms
      • Narrow your search for more hits

      How can we help?

      Contact Us

      Find Employees

      University of Skövde, link to startpage

      miRSeps - Future diagnostics of sepsis

      Research Group Infection Biology
      Resarch Environment Systems Biology

      miRSeps - Future diagnostics of sepsis

      Research Group Infection Biology
      Resarch Environment Systems Biology

      Quick Facts

      Full project name

      Future diagnostics of sepsis - miRSeps

      Duration

      January 2020 – December 2022

      Partners

      TATAA Biocenter AB, Unilabs AB, QIAGEN AB, Public healthcare Skaraborg Hospital, Swedish Institute for Standards.

      Financing

      Knowledge Foundation

      This project is one of several ongoing projects within the research programme “Future diagnostics for sepsis”. The aim is to develop diagnostics that can be used earlier in cases of sepsis in order to increase the patient’s chances of survival with fewer complications.

      Patients need to be identified as sepsis cases in order to reduce the mortality rate. The problem is that sepsis symptoms are often vague which makes the condition initially difficult to distinguish from less dangerous conditions such as norovirus (the winter vomiting bug) or influenza. Treatment of sepsis first and foremost involves treating its cause, if it is known.

      Antibiotics as treatment

      Sepsis is treated with antibiotics, preferably after culturing the bacteria and determining its antibiotic resistance. But often there is no time to wait for the culture results, and antibiotics that we know usually help from past experience are initiated until the culture results have come back. The sooner the correct diagnosis is made and the correct antibiotics are given in cases of sepsis, the greater the chance of the patient surviving and with fewer complications.

      Diagnosing sepsis in the future

      This project is one of several ongoing projects within the research programme “Future diagnostics for sepsis”. The aim is to develop earlier and more accurate diagnostics for cases of sepsis in order to increase the patient’s chances of survival with fewer complications.

      Early diagnosis – greater chance of survival

      The biomarkers used today in sepsis diagnostics cannot reliably identify patients with sepsis and there is a huge need for new diagnostic methods. We have previously analysed plasma samples from patients with suspected sepsis using high-throughput screening in order to measure the levels of free microRNA in the patients blood. The big amounts of data generated were then analysed to detect microRNAs which may help to identify patients with sepsis caused by bacteria.

      The project aims to validate multi-marker panels

      We have developed multi-marker panels, based on microRNAs combined with routine clinical biomarkers, that show promising diagnostic capabilities. The aim of this project is to validate these multi-marker panels by analysing additional patient samples using a new qPCR technology with a very high analytical sensitivity. We intend to also evaluate specific microRNAs as quality controls for the process from taking blood samples to the quantification of microRNAs.

      Project in media

      More information about Sepsis 

       

      Project leader

      Head of Division/Senior Lecturer in Systems Biology

      Participating Researchers

      Partners and financing

      Knowledge Foundation
      TATAA Biocenter AB
      Unilabs
      Västra Götaland Region